Collectively, these data indicate a rapid and determining effect of the high peptide dose vaccine on the selection of tumor antigen-specific CD8 T-cells bearing TCRs of low CD8 binding dependency (i.e., NTAmer-based CD8 binding-independent), already after 4 vaccine injections. This evidence concerns the gene CD8A and neoplasm.